Stephen Cohen, OD
Optometrist · Scottsdale, AZNPI 1891765921
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,788 of the $31,900 with a category attached, or 71.4%. Johnson & Johnson Vision Care, Inc. accounts for 74.3% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $9,623 and has fallen 88.6% since, to $1,095 in 2025. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $104.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$24K
- Coopervision Inc.$2K
- Biotissue Holdings Inc.$2K
- Alcon$770
- Sun Pharmaceutical Industries Inc.$615
- Dompe US, Inc.$483
- plus $2K from 20 others
Across 4 payments — averaging $7056.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$28K
What the payments were for
- Consulting fees$1,0003%
- Speaking & faculty fees$22,78871%
- Travel & lodging$1,2904%
- Food & beverage$6,73221%
- Education$270%
- Gifts$170%
- Entertainment$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 77 | $23,696 |
| Coopervision Inc. | 13 | $2,347 |
| Biotissue Holdings Inc. | 47 | $1,906 |
| Alcon | 23 | $770 |
| Sun Pharmaceutical Industries Inc. | 32 | $615 |
| Dompe US, Inc. | 15 | $483 |
| Bausch & Lomb Americas Inc. | 28 | $449 |
| Novartis | 18 | $373 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $276 |
| Oyster Point Pharma, Inc. | 5 | $235 |
| AbbVie | 6 | $101 |
| Tarsus Pharmaceuticals, Inc. | 4 | $86 |
| Eyevance Pharmaceuticals LLC | 5 | $83 |
| Maculogix, Inc. | 3 | $80 |
| Kala Pharmaceuticals, Inc. | 3 | $68 |
| Sight Sciences, Inc. | 2 | $57 |
| Optos, Inc. | 1 | $46 |
| Harrow Eye, LLC | 2 | $39 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $35 |
| Carl Zeiss Meditec, Inc. | 1 | $26 |
| Amgen | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| ABB Con-cise Optical Group LLC | 1 | $21 |
| Lumenis, Inc | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$22,463
- Non-Product Brand Specific$2,082
- Prokera$648
- AmnioGraft$648
- Precision 7$150
- Ryzumvi$127
- Oxervate$121
- ORA$113
- Precision 1$109
How this compares
$31,900 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 54 | $38,784 |
| XiidraLifitegrast | 22 | $24,676 |
| MieboPerfluorohexyloctane/Pf | 24 | $17,748 |
| Cyclosporine | 35 | $12,089 |
| LumiganBimatoprost | 18 | $7,374 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $256 |
| Latanoprost | 26 | $235 |
| Timolol Maleate | 12 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $101 | $46,15872 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $449 | $42,42446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Scottsdale
- Marc BloomensteinScottsdale$1.4M
- Andrew ZagelbaumScottsdale$25K
- Amanda GoldbergScottsdale$7K
- Daxa LadScottsdale$6K
- Tracy HutchingsScottsdale$6K
- Stephanie WooLake Havasu City$538K
- Jashpal RajasansiGilbert$104K
- Jamie KuhnGlendale$37K
- Tania SobchukLake Havasu City$32K
- Linda TrinhPeoria$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.